Adenocarcinoma of the Prostate
Conditions
Keywords
radiotherapy
Brief summary
Stereotaxic prostatic radiotherapy on Linac MRI, with monitoring of movements of the pelvic organs per fraction on the prostate in real time, in 4 sessions, with integrated boost on the index tumor (if it is visible on the diagnostic MRI), could reduce the digestive, urinary and sexual toxicities accumulated at 5 years and guarantee excellent local tumor control, for patients with localized prostate cancer, with a favorable prognosis, intermediate or very local high risk, according to the D'Amico classification. The benefits that patients participating in this research could obtain are: * Better disease control efficiency * A reduction in the duration of treatment to 4 radiotherapy sessions (2 weeks maximum) instead of 40 sessions (8 weeks) for usual treatment. * Avoid the risks associated with the implantation of prostate markers necessary for stereotaxic radiotherapy on a standard accelerator (anesthetic risks, infectious risks, hemorrhagic risks, pain risks) * Better quality of life
Interventions
RADIATIONStereotactic Radiotherapy with Linac MRI
38 Gy in 4 fractions of 9.5 Gy over the entire prostate, +/- 2 Gy in 4 fractions of 0.5 Gy as an integrated boost on the index tumor if it is visible on diagnostic multiparametric MRI (PIRADS-V2 score 4 or 5) and on planning MRI performed on Linac MRI.
Sponsors
Centre Georges Francois Leclerc
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
18 Years to 85 Years
Healthy volunteers
No
Inclusion criteria
1. prostate adenocarcinoma 2. WHO performance index ≤ 1 3. Patient presenting one of the following cases: * Low risk: ≤ T2a and Gleason 6 (3 + 3) and PSA \<10 ng / ml * Intermediate risk: T2b-T2c or Gleason 7 or PSA \<15 ng / ml * High localized risk: T3a and Gleason ≤7 and PSA \<15 ng / ml 4. Disease presenting a risk of lymph node involvement \<15% 5. Absence of pelvic or lumbar aortic lymphadenopathy 6. Absence of bone or visceral metastasis 7. IPSS score \<15 or ≤ 7 8. Prostate volume estimated by MRI or ultrasound \< 90cc 9. If hormonotherapy, hormone therapy must not have started for more than 60 days before inclusion. 10. Absence of prior pelvic radiotherapy 11. No surgical treatment for prostate cancer
Exclusion criteria
1. Prostate cancer of histology other than adenocarcinoma 2. Contraindication to MRI including, but not limited to, patients with a pacemaker or defibrillator 3. Patient diagnosed N1 during imaging workup or pN1 4. Serum PSA level ≥ 15 ng / ml 5. IPSS score ≥ 15 or IPSS score\> 7 if alpha blocking urological treatment in progress 6. Prostate volume estimated on MRI or ultrasound\> 90 cc 7. Involvement of seminal vesicles on MRI 8. History of cancer in the 5 years preceding entry into the trial 9. History of transurethral resection of the prostate less than 6 months compared to the expected date of start of radiotherapy 10. rectal surgery 11. pelvic irradiation 12. Patient treated with antineoplastic or medication which may include Methotrexate 13. Hormone therapy started for more than 60 days at the time of inclusion 14. Severe uncontrolled hypertension 15. Patient followed or treated for severe or unstable angina, or having presented a myocardial infarction in the 6 months preceding the randomization 16. Patient on immunosuppressant 17. Patient with known hypersensitivity to gadoteric acid, meglumine or any drug containing gadolinium
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Late gastrointestinal and urinary toxicity grade ≥ 2 | 5 years | toxicities graded according to the NCI-CTCAE-V5.0 |
Countries
France
Outcome results
None listed